

Forschungsprojekte 2016

Projets de recherche 2016

Unterstützt von: / Soutenus par:

krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research

Grundlagenforschung / Recherche fondamentale			
<u>Gesuchsteller/In</u>	<u>Projektnummer</u> <u>Projekttitel</u>	<u>Dauer</u> <u>(Monate)</u>	<u>Betrag</u> <u>(CHF)</u>
<u>Candidat/e</u>	<u>Numéro du projet</u> <u>Titre du projet</u>	<u>Durée</u> <u>(mois)</u>	<u>Montant</u> <u>(CHF)</u>
Aceto Nicola, Dr. Department of Biomedicine University of Basel 4058 Basel	KFS 3811-02-2016 The role of hypoxia in the generation of circulating tumour cell clusters	18	167 700.–
Carbone Giuseppina, Dr Laboratory of Experimental Oncology Istituto oncologico della Svizzera italiana (IOSI) 6500 Bellinzona	KFS 3872-02-2016 Functional, clinical and therapeutic impact of epigenetic cross-talks in ERG fusion positive prostate cancers	24	246 050.–
Ciriello Giovanni, Dr Computational Biology University of Lausanne 1011 Lausanne	KFS 3983-08-2016 Dissecting the landscape of cancer epigenetic modifications to discover novel oncogenic and actionable targets	48	286 950.–
Coppi Roberto, Prof. Cell Physiology and Metabolism University of Geneva 1211 Geneva	KFS 3794-02-2016 Beating cancer by hindering its stem-like attributes	36	375 000.–
Grzmil Michal, Dr. rer. nat. Center for Radiopharmaceutical Sciences Paul Scherrer Institut (PSI) 5232 Villigen PSI	KFS 3960-08-2016 Identification of sensitizing targets to radiopharmaceuticals for cancer treatment	36	220 000.–
Haefliger Jacques-Antoine, Prof. Département de physiologie Centre hospitalier universitaire vaudois (CHUV) 1005 Lausanne	KFS 3796-02-2016 Targeting the endothelial connexin37 and connexin40 to reduce tumour growth by altering angiogenesis	36	363 600.–

Hall Jonathan , Prof. Institut für Pharmazeutische Wissenschaften ETH Zürich 8093 Zürich	KFS 3816-02-2016 Determining the drugability of Lin28- dependent cancers	24	249 500.–
Hanahan Douglas , Prof. Swiss Institute for Experimental Cancer (ISREC) Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne 15	KFS 3878-02-2016 Comparing the effects of distinctive macrophage reprogramming agents on tumour associated macrophages to optimize immunotherapy	36	369 850.–
Hediger Matthias , Prof. Institute of Biochemistry and Molecular Medicine University of Bern 3000 Bern	KFS 3966-08-2016 The role of neutral amino acid transporters in colorectal cancer progression	36	373 600.–
Ho Ping-Chih , Dr Fundamental Oncology Ludwig Center of Cancer Research at the University of Lausanne (UNIL) 1066 Epalinges	KFS 3949-08-2016 CD36-mediated metabolic adaptation guides formation of intratumoural regulatory T-cells and restrains their metabolic vulnerability	36	247 400.–
Hugues Stephanie , Prof. Département de pathologie et d'immunologie Université de Genève (UNIGE) 1211 Genève	KFS 3950-08-2016 How MHCII-restricted antigen-presentation by lymphatics impacts tumour immunity	36	291 600.–
Ittig Simon , Dr. Biozentrum Universität Basel 4056 Basel	KFS 3798-02-2016 Bacterial cancer therapy: efficacy studies in mouse models of cancer	18	187 150.–
Janscak Pavel , PD Dr. Institut für Molekulare Krebsforschung (Doppelinstitut MeF/MNF) (IMCR) Universität Zürich (UZH) 8057 Zürich	KFS 3802-02-2016 Molecular basis of oncogene-induced DNA damage	36	210 450.–
Joyce Johanna , Prof. Department of Oncology University of Lausanne (UNIL) 1066 Epalinges	KFS 3990-08-2016 Targeting tumour-associated macrophages to enhance therapeutic efficacy in gliomas	36	374 300.–
Lopes Massimo , Prof. Institute of Molecular Cancer Research University of Zurich 8057 Zürich	KFS 3967-08-2016 Mechanisms of fork protection by the oncosuppressor BRCA2, as molecular determinants of cancer chemotherapy	36	370 250.–

Manz Markus , Prof. Klinik für Hämatologie UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS 3846-02-2016 Treating acute myeloid leukaemia with novel antibody therapies	36	242 450.–
Meraldi Patrick , Prof. Dr. Faculty of Medecine University of Geneva 1211 Geneva	KFS 3978-08-2016 Investigating cyclin E overexpression as a potential target for anti-mitotic drugs	12	118 050.–
Nadal David , Prof. Abteilung Infektiologie und Spitalhygiene Kinderspital Zürich 8032 Zürich	KFS 3958-08-2016 T-helper cells promote AIF-catalyzed mutagenesis in paediatric B acute lymphoblastic leukaemia	36	365 950.–
Nikolaev Sergey , Dr Bioinformatique clinique Hôpitaux universitaires de Genève (HUG) 1211 Genève	KFS 3985-08-2016 Investigation of the whole genome mutational landscape of basal cell carcinoma for the identification of non-coding drivers and properties of UV-light induced mutagenesis	48	310 000.–
Nombela Arrieta Cesar , Prof. Dr. Hematology University of Zurich 8091 Zurich	KFS 3986-08-2016 Structural and functional dynamics of the effects of acute myeloid leukaemia development and regression in the BM stromal microenvironment	48	325 000.–
Ochsenbein Adrian Franz , Prof. Dr. med. Klinik und Poliklinik für Onkologie Inselspital Bern 3010 Bern	KFS 3815-02-2016 IL-33/ST2 signalling in leukaemia stem cells	36	361 700.–
Oricchio Elisa , Ass. Prof. ISREC-SV Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS 3982-08-2016 Establishing the functional and therapeutic impact of Sestrin1 inactivation in follicular lymphoma	36	247 400.–
Petrova Tatiana , Prof. Dr Department of Fundamental Oncology CHUV and University of Lausanne (UNIL) 1066 Epalinges	KFS 3933-08-2016 Understanding vulnerabilities of tumour vasculature in distinct colorectal cancer subtypes	36	362 700.–
Piscuoglio Salvatore , Dr Pathology Basel University Hospital 4031 Basel	KFS 3995-08-2016 Identification of molecular targets in hepatocellular carcinomas associated with HMGA1 overexpression	24	158 950.–
Reith Walter , Prof. Dr Faculté de médecine Université de Genève (UNIGE) 1211 Genève	KFS 3870-02-2016 The BTN2A2-dependent immunoregulatory pathway as a new target for cancer immunotherapy	36	375 000.–

Riggi Nicolo , Prof. Département de pathologie Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	KFS 3973-08-2016 Identification of the epigenetic determinants of cellular transformation and progression in clear cell sarcoma	36	369 800.–
Sartori Alessandro A. , Prof. Dr. Institut für Molekulare Krebsforschung (Doppelinstitut MeF/MNF) (IMCR) Universität Zürich (UZH) 8057 Zürich	KFS 3845-02-2016 Peptide-based inhibitors of CtIP protein- protein interactions: from basic tools to cancer treatment	36	245 900.–
vom Berg Johannes , Dr. Institute of Laboratory Animal Science (LTK) University of Zurich 8091 Zurich	KFS 3852-02-2016 Further development of the local IL-12 immunotherapy of brain cancer in preparation of two large animal studies	8	81 000.–
Wälchli Thomas , Dr. Division of Neurosurgery and Laboratory for Molecular Neurooncology University Hospital Zurich 8091 Zurich	KFS 3880-02-2016 Nogo-A is a negative regulator of CNS angiogenesis - molecular mechanisms and applications in brain tumours	36	300 900.–
Weber Bruno , Prof. Institute of Pharmacology & Toxicology University of Zurich 8057 Zurich	KFS 3997-08-2016 In vivo real-time imaging of the impact of ionizing radiation on cellular energy metabolism	18	153 850.–
Wehrle-Haller Bernhard , Prof. Département de physiologie cellulaire et métabolisme Université de Genève (UNIGE) 1211 Genève	KFS 3856-02-2016 Integrin acetylation: controlling cancer cell adhesion, growth and ECM assembly	48	272 650.–

Klinische Forschung / Recherche clinique			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Ansari Marc , Dr Unité d'onco-hématologie pédiatrique Hôpitaux universitaires de Genève (HUG) 1211 Genève	KFS 3936-08-2016 The children's hepatic international collaboration (CHIC)	36	68 100.–
Beer Hans-Dietmar , PD Dr. Dermatologische Klinik UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS 3940-08-2016 Survival or death: the molecular mechanisms underlying the antagonistic links between Nrf2 and inflammasomes in skin cancer	36	242 450.–
Digklia Antonia , Dr med. Département Oncologie Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	KFS 3944-08-2016 NAPAGE: a phase IIa clinical trial of gemcitabine and nab-paclitaxel in advanced soft tissue sarcoma	36	182 900.–
Fierstra Jorn , Dr.med. et Dr. rer. nat. Neurosurgery University Hospital Zurich 8091 Zurich	KFS 3975-08-2016 Unravelling glioblastoma imaging complexity: novel quantitative phenotype-genotype mapping with functional MRI	24	220 850.–
Gillessen Sommer Silke , Prof. Dr. med. Bereich Onkologie / Hämatologie Kantonsspital St. Gallen (KSSG) 9007 St.Gallen	KFS 3874-02-2016 A phase III trial of Aspirin and Pravastatin in patients with castrate-resistant prostate cancer (Peace 4)	36	373 900.–
Grochola Lukasz Filip , Dr. med. Visceral- and Transplantation Surgery University Hospital Zurich 8400 Winterthur	KFS 3697-08-2015 The identification and functional analysis of inherited human genetic variants that affect the prognosis and therapy of pancreatic cancer	12	125 000.–
Guckenberger Matthias , Prof. Dr. Klinik für Radio-Onkologie UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS 3956-08-2016 Dose-intensified image-guided fractionated stereotactic body radiotherapy for painful spinal metastases (DOSIS) versus conventional radiation therapy: a phase II randomized controlled trial	36	179 500.–
Hegi Monika , Prof. Service de neurochirurgie Centre hospitalier universitaire vaudois (CHUV) 1066 Epalinges	KFS 3998-08-2016 Characterizing invasiveness of patient derived glioblastoma xenografts by gene expression profiling in association with in vivo 1H magnetic resonance spectroscopy (MRS) and MR imaging. A pilot project	12	115 500.–

<p>Jacob Francis, Dr. Department of Biomedicine University Hospital Basel 4031 Basel</p>	<p>KFS 3841-02-2016 Functional characterization of bisecting GlcNAc-dependent signalling pathways for the intervention of serous ovarian cancer omental metastasis</p>	36	340 150.–
<p>Joerger Markus, PD Dr. med. et rer. nat. Departement Onkologie/Hämatologie Kantonsspital St. Gallen (KSSG) 9007 St.Gallen</p>	<p>KFS 3943-08-2016 Enzalutamide in combination with metformin versus enzalutamide in patients with castration-resistant prostate cancer progressing on androgen deprivation therapy (SAKK 08/14): a mass spectrometry-based, quantitative systemic metabolomics substudy</p>	36	99 600.–
<p>Lengerke Claudia, Prof. Dr. med. Clinic for Hematology and Department of Biomedicine University Hospital Basel 4031 Basel</p>	<p>KFS 4013-08-2016 Investigation of catecholamine-based mechanisms regulating leukaemia induction in a xenotransplantation model of human AML</p>	30	307 300.–
<p>Matter Matthias, Dr. Dr. med. et phil nat. Institut für Pathologie Universitätsspital Basel 4031 Basel</p>	<p>KFS 3876-02-2016 Identification of mechanisms that promote liver cancer</p>	12	125 000.–
<p>Mazzucchelli Luca, Prof. Dr med. Patologia Istituto cantonale di patologia 6601 Locarno</p>	<p>KFS 3977-08-2016 Role of BCL2 genetic heteroclonality in the pathogenesis of B-cell lymphomas with BCL2 rearrangement</p>	36	255 200.–
<p>Meyer Sara Christina, Dr. med. Hematology University Hospital Basel 4031 Basel</p>	<p>KFS 3858-02-2016 Dual targeting of oncogenic MAPK- and tyrosine kinase signalling as therapeutic approach in myeloid malignancies</p>	24	239 650.–
<p>Omlin Aurelius, Dr. med. Departement Medizinische Onkologie und Hämatologie Kantonsspital St. Gallen (KSSG) 9007 St.Gallen</p>	<p>KFS 3999-08-2016 Single arm open label phase II pilot study of carboplatin in patients with metastatic castration-resistant prostate cancer (CRPC) and DNA repair defects</p>	30	100 500.–
<p>Pabst Thomas, Prof. Dr. Institut für medizinische Onkologie Inselspital Bern 3010 Bern</p>	<p>KFS 3795-02-2016 Evolving concepts of stem cell mobilization and high-dose chemotherapy for patients with myeloma</p>	24	112 700.–
<p>Papadia Andrea, Dr. med. Gynäkologie Inselspital Bern 3010 Bern</p>	<p>KFS 3969-08-2016 Prospective validation trial on indocyanine- green sentinel lymph node mapping in endometrial cancer</p>	36	126 750.–

Peng Ren-Wang , Dr. Universitätsklinik für Thoraxchirurgie Inselspital Bern 3010 Bern	KFS 3772-08-2015 Unravelling and reversing drug resistance of human lung cancer	36	229 850.–
Pica Alessia , Dr. med. Protontherapy Center Paul Scherrer Institut (PSI) 5232 Villigen	KFS 3860-02-2016 High resolution ophthalmic magnetic resonance imaging at 1.5T: towards a non- invasive method to assist proton therapy planning for uveal melanoma	36	302 000.–
Pruschy Martin , Prof. Dr. sc. nat. Departement für Medizinische Radiologie UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS 3993-08-2016 Targeting ADAM17 in combination with ionizing radiation	36	375 000.–
Reyes Mauricio , Prof. Dr Institute for Surgical Technology and Biomechanics University of Bern 3014 Bern	KFS 3979-08-2016 Multidimensional response assessment in glioma patients – MANAGE	48	370 600.–
Sessa Cristiana , Prof. Dr. Ospedale Regionale Bellinzona e Valli (ORB) Istituto oncologico della Svizzera Italiana (IOSI) 6500 Bellinzona	KFS 3875-02-2016 IVINCA trial (Ivermectin IN CANcer), phase I trial of ivermectin as an anticancer WNT-TCF response inhibitor in patients with solid tumours	36	156 800.–
Simon Christian , Prof. Service d'oto-rhino-laryngologie Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	KFS 3761-08-2015 SAKK EORTC 1420 GORTEC: phase III study assessing the “best of” radiotherapy (IMRT) compared to the “best of” surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0 oropharyngeal carcinomas	48	150 000.–
Speiser Daniel E. , Prof. Dr med. Department of Oncology University of Lausanne 1066 Epalinges	KFS 3971-08-2016 Local, regional and systemic mechanisms of T-cell inhibition in melanoma, associated with lymphatic endothelial/stromal cells	36	362 600.–
von Gunten Stephan , Prof. Dr. Institut für Pharmakologie Universität Bern 3010 Bern	KFS 3941-08-2016 Siglecs - implications of tumour hypersialylation on cytotoxic T-cell responses	36	375 000.–
Zaidi Habib , Prof. Dr Radiology and Medical Informatics Hôpitaux universitaires de Genève (HUG) 1211 Genève	KFS 3855-02-2016 Towards MRI-only or PET/MRI- guided radiation therapy treatment planning	36	255 250.–

Zucca Emanuele , PD Dr med. Oncology Institute of Southern Switzerland Ente Ospedaliero Cantonale 6500 Bellinzona	KFS 4003-08-2016 High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trial (MATRix/IELSG43)	36	362 900.–
--	---	----	-----------

Psychosoziale Forschung / Recherche psychosociale			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Eicher Manuela , Prof. Dr rer. med. Institut universitaire de formation et de recherche en soins Université de Lausanne (UNIL) 1010 Lausanne	KFS 3823-02-2016 Co-creating and testing the effectiveness of an integrated peer-to-peer self-management programme for breast cancer survivors: a stepped wedge cluster randomized study (COSS-Study)	12	75 000.–
Michel Gisela , Prof. Health Sciences and Health Policy University of Lucerne 6002 Lucerne	KFS 3955-08-2016 Improving follow-up care of childhood cancer: implementation of screening for psychological distress	36	199 450.–

Epidemiologische Forschung / Recherche épidémiologie			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Clough-Gorr Kerri , Prof. Dr. Medical Faculty Institute of Social and Preventive Medicine (ISPM) 3012 Bern	KFS 3862-02-2016 An update of cancer risk in persons infected with HIV in Switzerland - continued - analysis and results	24	177 000.–
Rapiti Elisabetta , Dr Geneva Cancer Registry Global Health Institute University of Geneva 1205 Geneva	KFS 3932-08-2016 Importance of family history of cancer on colorectal cancer occurrence and outcome: population-based study in Geneva	24	200 250.–
Spycher Ben D. , Dr Institute of Social and Preventive Medicine (ISPM) University of Bern 3012 Bern	KFS 4012-08-2016 Spatial variation of childhood cancer risk in Switzerland and associations with traffic- related air pollution	24	272 600.–

Stipendien 2016

Bourses 2016

Unterstützt von: / Soutenus par:

krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research

Gesuchsteller/In	Projektnummer Projekttitle	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Dubouchet Laetitia , Dr Pediatric Department Hospital of Nyon 1260 Nyon	BIL KFS 3988-08-2016 Toward immune biomarkers for tolerance and Graft-Versus-Host-Disease (GVHD) after allogeneic haematopoietic stem cell transplantation in humans Destination: Service d'hématologie Greffe, Hôpital Saint-Louis, Paris, F	24	90 500.–
Jin Julie , cand. med. Medizinische Fakultät Universität Basel 4058 Basel	MD-PhD 3916-06-2016 SAMW MD-PhD Stipendium Phosphoinositide 3-kinase γ : adapter subunit-dependent activation in inflammation and allergy Destination: Departement für Biomedizin, Universität Basel, Basel	36	180 000.–
Saner Flurina Anna-Carina Maria , Dr. med. Gynaecology and Obstetrics Basel University Hospital 4031 Basel	BIL KFS 3942-08-2016 Genetic determinants for treatment response and survival in women with high grade serous ovarian cancer Destination: Cancer Genomics and Genetics Program, Peter MacCallum Cancer Center, Melbourne Victoria, AUS	24	29 250.–
Wettstein Marian Severin , med. prakt. Urology UniversitätsSpital Zürich (USZ) 8091 Zürich	BIL KFS 4009-08-2016 Underutilization of re-resection in T1 bladder cancer and the impact on oncological outcomes – a population-based study Destination: Division of Urology, Princess Margaret Cancer Center, Toronto, CAN	24	96 000.–